<DOC>
	<DOCNO>NCT02714621</DOCNO>
	<brief_summary>The primary objective pilot study determine whether feasible use MRgHIFU treat symptomatic ( pain , bleed ) recurrent pelvic malignancy acceptable safety profile conventional treatment option available . The ultimate goal able offer viable method symptom palliation patient recurrent pelvic tumour improve quality life; also control tumour growth extend life group relatively young patient isolated local recurrence .</brief_summary>
	<brief_title>MR-HIFU Recurrent Gynaecological Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<criteria>Patients recurrent pelvic gynaecological malignancy ( cervix endometrial cancer ) . Recurrent lesion painful ( NRS &gt; 4 ) suitable alternative treatment Intended target volume accessible MRgHIFU treatment Intended target volume visible noncontrast MR image Distance target skin ≥1cm MRI contraindicate ( e.g . incompatible metal implant claustrophobia ) Pregnancy Sedation contraindicate MRI contrast agent contraindicate Scar , internal external fixation device along beam path target</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Magnetic Resonance Imaging ( MRI )</keyword>
	<keyword>High Intensity Focused Ultrasound ( HIFU )</keyword>
	<keyword>Focused Ultrasound Surgery</keyword>
</DOC>